Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD ...Middle East

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules...

Hence then, the article about ark biopharmaceutical receives china marketing authorization for azstarys for the treatment of adhd was published today ( Tuesday 06/01/2026 - 09:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD )

Also on site :

• Seizure of Russian-flagged oil tanker: what we know so far
• 'TV star Nick Owen recovering from second cancer scare - Midlands Today presenter reveals he has had surgery for disease in his kidney
• Fatal I-55 crash shuts down lanes in southwest suburbs; ‘major' traffic backups expected